{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:56:30Z","timestamp":1768506990356,"version":"3.49.0"},"posted":{"date-parts":[[2023,6,29]]},"group-title":"Molecular Biology","reference-count":16,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Recent advances in liver cancer treatments have not changed the fact that the majority of patients will not survive the disease. In order to advance future liver cancer treatments, this work presents an exploration of various iterations of the liver cancer specific AFP promoter as well as the gene construct p53-Bad*. p53-Bad* is a mitochondrially targeted re-engineered p53 therapy that has shown previous success in a zebrafish HCC model. Both the most promising AFP promoter and p53-Bad* were packaged in an adenoviral delivery system and tested in vitro in liver cancer cell lines. Finally, mixed results for adenoviral p53-Bad* in vivo are presented, and this work suggests future modifications to study parameters in order to further explore the potential of p53-Bad* as a potential liver cancer therapeutic.<\/jats:p>","DOI":"10.1101\/2023.06.29.547129","type":"posted-content","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:25Z","timestamp":1688083225000},"source":"Crossref","is-referenced-by-count":0,"title":["p53-Bad* in a Hepatocellular Carcinoma Mouse Model"],"prefix":"10.64898","author":[{"given":"Katherine Redd","family":"Bowman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"issue":"10360","key":"2023070411500989000_2023.06.29.547129v1.1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"2023070411500989000_2023.06.29.547129v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2020.10.001"},{"key":"2023070411500989000_2023.06.29.547129v1.3","unstructured":"Administration, U. S. F. a. D. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma. https:\/\/www.fda.gov\/drugs\/resources-informaon-approved-drugs\/fda-approves-tremelimumab-combinaon-durvalumab-unresectable-hepatocellular-carcinoma (accessed 6\/20\/23)."},{"issue":"1","key":"2023070411500989000_2023.06.29.547129v1.4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/acs.molpharmaceut.2c00665","article-title":"p53-Bad* Fusion Gene Therapy Induces Apoptosis In Vitro and Reduces Zebrafish Tumor Burden in Hepatocellular Carcinoma","volume":"20","year":"2023","journal-title":"Mol. Pharm"},{"issue":"8","key":"2023070411500989000_2023.06.29.547129v1.5","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1021\/acs.molpharmaceut.9b00136","article-title":"p53-Bad: a novel tumor suppressor\/proapoptotic factor hybrid directed to the mitochondria for ovarian cancer gene therapy","volume":"16","year":"2019","journal-title":"Mol. Pharm"},{"key":"2023070411500989000_2023.06.29.547129v1.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419"},{"issue":"4","key":"2023070411500989000_2023.06.29.547129v1.7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3892\/mco.2013.119","article-title":"Tumor markers for hepatocellular carcinoma","volume":"1","year":"2013","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"2023070411500989000_2023.06.29.547129v1.8","doi-asserted-by":"crossref","first-page":"12870","DOI":"10.1038\/s41598-017-12834-1","article-title":"The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma","volume":"7","year":"2017","journal-title":"Sci. Rep"},{"issue":"27","key":"2023070411500989000_2023.06.29.547129v1.9","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.3748\/wjg.v22.i27.6127","article-title":"Alpha-fetoprotein-targeted reporter gene expression imaging in hepatocellular carcinoma","volume":"22","year":"2016","journal-title":"World J. Gastroenterol"},{"key":"2023070411500989000_2023.06.29.547129v1.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053072"},{"issue":"1","key":"2023070411500989000_2023.06.29.547129v1.11","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/s41598-018-20268-6","article-title":"Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions","volume":"8","year":"2018","journal-title":"Sci. Rep"},{"issue":"6","key":"2023070411500989000_2023.06.29.547129v1.12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/07357900802620885","article-title":"AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma","volume":"27","year":"2009","journal-title":"Cancer Invest"},{"issue":"1","key":"2023070411500989000_2023.06.29.547129v1.13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13048-019-0514-4","article-title":"Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer","volume":"12","year":"2019","journal-title":"J. Ovarian Res"},{"issue":"1","key":"2023070411500989000_2023.06.29.547129v1.14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.carj.2013.05.004","article-title":"Extrahepatic Metastases of Hepatocellular Carcinoma: A Spectrum of Imaging Findings","volume":"65","year":"2014","journal-title":"Can. Assoc. Radiol. J"},{"key":"2023070411500989000_2023.06.29.547129v1.15","unstructured":"Karina Julia, M. , Targeting p53 and its domains for cancer gene therapy. Philipps-Universit\u00e4t Marburg: 2014."},{"issue":"3","key":"2023070411500989000_2023.06.29.547129v1.16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.celrep.2018.06.059","article-title":"Promoter Activity Buffering Reduces the Fitness Cost of Misregulation","volume":"24","year":"2018","journal-title":"Cell Rep"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.06.29.547129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:51:25Z","timestamp":1768452685000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2023.06.29.547129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1101\/2023.06.29.547129","relation":{},"subject":[],"published":{"date-parts":[[2023,6,29]]},"subtype":"preprint"}}